ReShape Lifesciences (RSLS) stock price, revenue, and financials

ReShape Lifesciences market cap is $1.9 m, and annual revenue was $606.71 k in FY 2018

$1.9 M

RSLS Mkt cap, 27-Mar-2020

$3.5 M

ReShape Lifesciences Revenue Q3, 2019
ReShape Lifesciences Gross profit (Q3, 2019)2.1 M
ReShape Lifesciences Gross profit margin (Q3, 2019), %59.8%
ReShape Lifesciences Net income (Q3, 2019)-28.8 M
ReShape Lifesciences EBIT (Q3, 2019)-5.6 M
ReShape Lifesciences Cash, 30-Sept-20197.7 M
ReShape Lifesciences EV-5.2 M

ReShape Lifesciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

311.5k292.0k786.7k1.3m606.7k

Revenue growth, %

(6%)169%

Cost of goods sold

231.5k125.0k431.5k936.4k164.3k

Gross profit

80.0k167.0k355.2k350.8k442.4k

Gross profit Margin, %

26%57%45%27%73%

R&D expense

16.7m10.7m11.1m11.0m8.1m5.2m5.8m5.7m

General and administrative expense

8.6m12.0m13.7m14.6m19.9m18.0m26.0m19.3m

Operating expense total

25.3m22.6m24.7m25.6m28.0m23.2m31.8m39.0m

EBIT

(22.5m)(24.7m)(25.6m)(27.9m)(22.8m)(31.4m)(38.5m)

EBIT margin, %

(7239%)(9543%)(2898%)(2440%)(6353%)

Interest expense

722.9k901.8k

Interest income

12.2k9.9k5.7k3.3k1.8k5.8k1.1k

Pre tax profit

(36.1m)(38.7m)

Income tax expense

(2.3m)(3.4m)

Net Income

(26.0m)(23.5m)(25.8m)(26.1m)(25.5m)(23.4m)(33.8m)(81.2m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

123.1k188.4k79.0k64.0k72.0k276.0k296.8k40.0k93.1k360.0k950.0k653.4k350.2k3.1m4.5m3.5m

Cost of goods sold

85.5k146.0k30.8k23.3k40.1k155.3k146.6k29.5k54.5k214.5k829.0k634.8k263.9k843.0k1.6m1.4m

Gross profit

37.6k42.4k48.2k40.7k31.9k120.7k150.1k10.5k38.6k145.5k121.0k18.6k86.3k2.2m2.9m2.1m

Gross profit Margin, %

31%23%61%64%44%44%51%26%41%40%13%3%25%73%64%60%

R&D expense

3.3m4.8m2.7m2.2m2.6m2.7m2.7m2.8m2.6m3.1m2.3m2.2m2.5m1.8m1.4m1.2m1.3m1.1m1.4m1.1m2.7m2.4m1.3m1.1m960.0k858.0k

General and administrative expense

2.1m2.4m2.8m2.5m3.0m3.6m3.4m3.2m3.9m4.3m3.3m4.7m4.9m4.3m6.1m5.6m3.4m5.9m5.6m4.6m10.0m6.7m6.4m5.4m6.8m5.4m

Operating expense total

5.4m7.1m5.5m4.8m5.6m6.3m6.1m6.0m6.6m7.4m5.6m7.0m7.4m6.1m7.6m6.8m4.6m7.1m6.9m5.7m12.7m36.3m7.6m6.5m14.3m7.7m

EBIT

(5.5m)(4.7m)(5.6m)(6.3m)(6.1m)(6.0m)(6.6m)(7.4m)(5.6m)(7.0m)(7.3m)(6.0m)(7.5m)(6.7m)(4.5m)(7.0m)(6.9m)(5.6m)(12.6m)(36.3m)(7.5m)(4.2m)(11.5m)(5.6m)

EBIT margin, %

(4457%)(2510%)(9292%)(9391%)(10475%)(2412%)(1505%)(17590%)(7387%)(1544%)(1328%)(5559%)(2154%)(138%)(258%)(160%)

Interest expense

164.3k167.8k143.6k229.3k263.7k261.1k247.6k565.5k

Interest income

1.1k2.3k1.6k2.6k3.2k2.2k1.4k1.2k1.0k746.0755.0867.0422.0157.01.7k1.8k1.5k100.0411.0263.0217.0

Pre tax profit

(12.6m)(36.5m)(7.5m)(4.5m)(16.5m)(28.8m)

Income tax expense

(1.4m)(1.2m)(531.1k)(586.0k)

Net Income

(5.6m)(7.3m)(5.6m)(5.0m)(5.8m)(6.6m)(6.3m)(6.3m)(6.7m)(7.5m)(5.7m)(7.2m)(7.4m)(4.2m)(7.4m)(5.0m)(6.5m)(7.4m)(6.8m)(10.0m)(11.2m)(35.3m)(7.0m)(4.5m)(15.9m)(28.8m)

ReShape Lifesciences Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

27.2m32.4m20.5m26.6m27.2m29.4m23.1m21.1m24.4m21.7m16.3m11.4m4.8m12.3m11.2m11.5m6.8m18.7m11.2m23.4m841.6k1.9m472.9k1.8m4.4m7.7m

Accounts Receivable

123.1k16.9k52.6k18.6k17.0k53.3k1.5k112.5k25.1k55.0k182.5k191.7k68.2k109.4k333.1k962.4k446.0k532.1k3.9m4.6m3.0m

Prepaid Expenses

912.6k716.4k776.0k634.8k558.4k584.1k607.2k570.3k618.7k353.1k241.6k463.0k338.4k232.6k873.5k462.1k371.4k401.8k536.9k252.5k723.1k919.5k601.1k2.5m2.3m1.8m

Inventories

1.0m1.1m1.6m1.3m1.4m1.2m1.1m895.3k915.5k1.1m1.3m1.4m1.9m2.0m2.1m1.7m1.4m1.6m2.8m2.1m1.1m1.0m1.3m1.2m

Current Assets

28.3m36.4m23.6m29.5m29.6m31.5m25.3m23.1m26.1m22.9m17.4m13.0m6.5m13.9m14.0m14.1m9.5m20.9m13.3m25.6m5.3m5.3m2.7m9.2m12.6m13.7m

PP&E

616.8k568.3k625.2k650.2k629.8k592.0k563.9k632.5k536.9k491.4k462.3k446.9k416.0k367.0k298.4k259.2k228.5k171.6k240.5k195.5k349.3k303.2k181.2k47.0k27.0k6.0k

Goodwill

6.4m6.4m27.2m

Total Assets

29.1m37.0m24.6m30.5m30.7m33.2m26.9m24.7m27.6m24.4m18.9m14.3m7.9m15.0m14.9m15.0m10.6m21.7m42.5m55.2m78.6m50.5m47.1m47.4m43.7m44.2m

Accounts Payable

122.4k261.3k262.6k98.8k292.7k449.2k227.4k180.2k274.0k187.4k51.6k47.5k447.2k195.8k261.4k357.0k680.8k533.6k1.1m706.5k2.9m4.2m4.4m7.6m9.9m3.9m

Short-term debt

1.7m2.3m189.3k1.0m2.0m4.0m4.0m7.0m4.0m4.0m4.0m2.0m997.8k1.2k44.8k

Current Liabilities

4.7m6.3m4.9m4.7m6.3m8.8m8.3m8.4m8.4m8.8m8.4m7.0m6.5m3.7m9.4m10.3m8.0m3.7m4.5m4.1m8.8m8.7m8.8m11.8m12.2m11.7m

Long-term debt

4.0m3.4m4.5m9.9m9.9m10.1m9.1m3.8m1.9m932.1k700.0k626.0k552.0k

Total Debt

5.6m5.7m4.7m10.9m11.9m14.1m13.1m10.8m5.9m4.9m4.0m2.0m997.8k1.2k44.8k700.0k626.0k552.0k

Total Liabilities

8.6m9.7m9.4m13.3m13.9m14.5m13.0m12.3m10.3m9.7m8.4m7.0m6.5m7.3m16.1m18.6m9.4m3.8m4.5m4.1m12.7m11.4m11.0m18.9m30.3m59.8m

Common Stock

279.0k367.5k367.6k396.7k415.6k556.2k556.2k586.2k672.0k688.8k688.9k744.0k744.0k1.1m85.0k132.2k744.1k69.1k83.0k122.1k309.6k36.1k6.0k77.0k285.0k

Preferred Stock

10.0k

Additional Paid-in Capital

181.5m195.6m197.1m204.1m209.5m224.9m226.4m231.2m249.2m254.2m255.7m265.8m267.3m277.5m283.6m286.2m296.9m326.2m353.1m376.1m411.6m424.2m428.3m451.9m452.5m452.5m

Retained Earnings

(161.4m)(168.7m)(182.3m)(187.3m)(193.1m)(206.8m)(213.1m)(219.4m)(232.7m)(240.2m)(245.9m)(259.3m)(266.7m)(270.8m)(285.0m)(290.0m)(296.5m)(308.3m)(315.1m)(325.1m)(346.0m)(385.1m)(392.2m)(423.5m)(439.4m)(468.1m)

Total Equity

20.4m27.3m15.1m17.2m16.8m18.7m13.8m12.4m17.2m14.7m10.5m7.3m1.4m7.7m(1.3m)(3.6m)1.2m17.9m38.0m51.0m65.9m39.1m36.0m28.6m13.4m(15.7m)

Financial Leverage

1.4 x1.4 x1.6 x1.8 x1.8 x1.8 x1.9 x2 x1.6 x1.7 x1.8 x2 x5.5 x1.9 x-11.8 x-4.2 x9.2 x1.2 x1.1 x1.1 x1.2 x1.3 x1.3 x1.7 x3.3 x-2.8 x

ReShape Lifesciences Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(10.6m)(17.9m)(5.6m)(10.6m)(16.4m)(6.6m)(12.9m)(19.2m)(6.7m)(14.2m)(19.9m)(7.2m)(14.6m)(18.7m)(7.4m)(12.4m)(18.9m)(7.4m)(14.2m)(24.2m)(11.2m)(46.5m)(53.5m)(4.5m)(20.4m)(49.1m)

Depreciation and Amortization

143.3k223.6k68.0k125.6k177.6k42.1k81.6k124.4k47.5k95.0k141.9k48.7k97.4k146.3k39.4k78.7k109.4k29.1k68.8k158.6k764.5k1.5m2.3m433.0k863.0k1.3m

Accounts Receivable

(123.1k)(16.9k)(52.6k)(10.2k)(8.6k)(8.9k)17.7k17.7k17.7k1.3k(109.7k)(22.3k)2.9k(124.6k)(133.8k)75.5k34.3k(189.4k)(473.7k)42.6k(43.5k)(3.0m)(3.7m)(2.3m)

Inventories

65.9k(19.4k)(542.7k)(64.9k)(87.0k)98.9k36.8k232.7k212.4k(145.8k)(303.9k)(395.5k)(181.9k)(271.5k)(447.5k)86.7k272.3k(257.2k)21.8k716.1k1.8m(40.0k)(363.0k)(204.0k)

Accounts Payable

198.7k323.6k(187.6k)(431.7k)(271.2k)87.8k(127.9k)102.9k146.7k60.0k(75.8k)(347.2k)52.5k(198.9k)89.4k184.9k508.8k(778.1k)(388.6k)(788.2k)1.8m3.1m3.3m1.1m3.4m3.0m

Cash From Operating Activities

(9.3m)(14.5m)(7.4m)(12.5m)(17.0m)(5.0m)(10.2m)(14.1m)(5.6m)(10.6m)(15.0m)(5.6m)(11.2m)(17.2m)(6.9m)(12.5m)(17.1m)(4.4m)(10.1m)(15.7m)(9.3m)(15.8m)(20.4m)(5.7m)(8.6m)(12.9m)

Purchases of PP&E

(221.3k)(239.0k)(48.1k)(51.8k)(51.8k)(3.6k)(20.9k)(410.5k)(7.3k)(9.3k)(27.1k)(18.7k)(36.5k)(37.3k)(11.5k)(11.5k)(11.5k)(5.3k)(108.6k)(7.0k)(7.0k)

Cash From Investing Activities

6.1m3.1m(48.1k)(51.8k)948.2k(3.6k)(20.9k)(410.5k)(7.3k)(9.3k)(27.1k)(18.7k)(36.5k)(37.3k)(11.5k)(11.5k)(11.5k)(1.9m)(2.0m)(7.0k)(7.0k)

Short-term Borrowings

(367.2k)(367.2k)(563.5k)(752.8k)(752.8k)(1.0m)(2.0m)(1.0m)(2.0m)(3.0m)(1.0m)(2.0m)(3.0m)

Long-term Borrowings

(333.3k)(333.3k)(333.3k)(333.3k)

Cash From Financing Activities

(399.8k)13.0m(550.4k)10.6m14.8m12.1m11.0m13.4m6.7m9.0m8.0m5.5m4.4m17.9m10.1m16.1m16.0m19.8m19.8m37.8m7.5m10.7m2.0m7.4m15.1m

Net Change in Cash

(3.6m)1.6m(8.0m)(1.9m)(1.3m)7.1m778.8k(1.2m)1.1m(1.6m)(7.0m)(186.9k)(6.8m)641.8k3.2m3.6m(1.1m)15.4m7.9m20.1m(9.3m)(8.3m)(9.7m)(3.7m)(1.2m)2.2m

Interest Paid

264.3k359.5k82.5k(213.0k)(417.4k)200.0k397.6k574.7k133.6k249.4k344.7k53.6k87.6k601.2k163.2k163.2k169.3k

ReShape Lifesciences Ratios

USDY, 2019

EV/EBIT

0.9 x

EV/CFO

0.4 x

Financial Leverage

-2.8 x